Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The CKD-associated decline in soluble α-Klotho (α-Klotho) levels is considered detrimental.

This trial is registered in EudraCT ( 2013-003354-24 ).

Who Took Part

The study group was 8 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A prospective, single-center open case-control pilot study was performed involving 8 patients with mild CKD and 8 healthy controls matched for age and sex.

How the Study Was Run

The design is described as pilot.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

The CKD-associated decline in soluble α-Klotho (α-Klotho) levels is considered detrimental.

PubMed files the paper under topics including Biomarkers, Case-Control Studies, Glucuronidase, Growth Hormone, Klotho Proteins, Pilot Projects and Renal Insufficiency, Chronic.

The authors tagged it with the keywords Chronic kidney disease and α-Klotho.

What This Means in Plain Language

The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (BMC nephrology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.